Bright Minds Biosciences (DRUG) Assets Average (2021 - 2026)

Bright Minds Biosciences has reported Assets Average for 6 years, with the latest figure at $146.5 million in Q1 2026.

• For the quarter ending Q1 2026, Assets Average rose 260.95% year-over-year to $146.5 million; the trailing twelve-month figure through Mar 2026 stood at $146.5 million (up 260.95% YoY), and the FY2025 full-year result was $32.9 million, up 585.16% from the prior year.
• Assets Average for Q1 2026 stood at $146.5 million, up from $63.3 million in the prior quarter.
• The five-year high for Assets Average was $146.5 million in Q1 2026, with the low at $4.5 million in Q3 2024.
• Historically, Assets Average has averaged $25.7 million across 5 years, with a median of $8.1 million in 2022.
• Annual changes were most pronounced in 2022 — Assets Average plunged 52.39% — and 2025, when it jumped 994.67%.
• Bright Minds Biosciences' Assets Average stood at $8.9 million in 2022, then plunged by 42.68% to $5.1 million in 2023, then surged by 354.16% to $23.1 million in 2024, then soared by 173.37% to $63.3 million in 2025, then surged by 131.56% to $146.5 million in 2026.
• The last three Assets Average figures came in at $146.5 million (Q1 2026), $63.3 million (Q4 2025), and $49.6 million (Q3 2025), per Business Quant data.